Montalban-Bravo, Guillermo http://orcid.org/0000-0002-4533-5176
Rodriguez-Sevilla, Juan Jose
Swanson, David Michael
Kanagal-Shamanna, Rashmi http://orcid.org/0000-0001-7829-5249
Hammond, Danielle http://orcid.org/0000-0002-6017-2264
Chien, Kelly http://orcid.org/0000-0001-6024-1613
Sasaki, Koji http://orcid.org/0000-0002-9140-0610
Jabbour, Elias http://orcid.org/0000-0003-4465-6119
DiNardo, Courtney http://orcid.org/0000-0001-9003-0390
Takahashi, Koichi http://orcid.org/0000-0002-8027-9659
Short, Nicholas http://orcid.org/0000-0002-2983-2738
Issa, Ghayas C. http://orcid.org/0000-0002-4339-8683
Pemmaraju, Naveen http://orcid.org/0000-0002-1670-6513
Kadia, Tapan http://orcid.org/0000-0002-9892-9832
Ravandi, Farhad http://orcid.org/0000-0002-7621-377X
Daver, Naval http://orcid.org/0000-0001-7103-373X
Borthakur, Gautam http://orcid.org/0000-0001-7679-6453
Loghavi, Sanam http://orcid.org/0000-0001-8980-3202
Pierce, Sherry
Bueso-Ramos, Carlos
Kantarjian, Hagop http://orcid.org/0000-0002-1908-3307
Garcia-Manero, Guillermo http://orcid.org/0000-0002-3631-2482
Article History
Received: 2 January 2024
Revised: 13 February 2024
Accepted: 15 February 2024
First Online: 28 February 2024
Competing interests
: KS declares honoraria from Otsuka Pharma, and consultancy fee from Pfizer Japan. MK declares consulting and honoraria from AbbVie, Genentech, F. Hoffman La-Roche, Stemline Therapeutics, Amgen, Forty-Seven, and Kisoji; research funding and/or clinical trial support from AbbVie, Genentech, F. Hoffman La-Roche, Eli Lilly, Cellectis, Calithera, Ablynx, Stemline Therapeutics, Agios, Ascentage, and Astra Zeneca; and stock options/royalties from Reata Pharmaceutical. HK declares research support from AbbVie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi-Sankyo, Immunogen, Jazz Pharma, Novartis, and Pfizer, honoraria from AbbVie, Actinium, Agios, Amgen, Immunogen, Orsinex, Pfizer, and Takeda, and an advisory role with Actinium. GG-M declares support from and an advisory role with Celgene Corporation, Astex, and Amphivena, and grant/research support 15 from Helsinn, Novartis, AbbVie, Onconova, H3 Biomedicine, and Merck. The rest of authors declare no competing financial interests.